BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/2/2014 10:31:00 AM | Browse: 966 | Download: 882
Publication Name World Journal of Gastroenterology
Manuscript ID 6398
Country/Territory United States
Received
2013-10-16 12:48
Peer-Review Started
2013-10-17 18:30
To Make the First Decision
2013-12-03 18:58
Return for Revision
2013-12-05 11:02
Revised
2013-12-13 08:58
Second Decision
2014-01-05 14:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-05 15:19
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-02-24 16:08
Publish the Manuscript Online
2014-03-06 14:13
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?
Manuscript Source Invited Manuscript
All Author List Evan J Walker and Andrew H Ko
Funding Agency and Grant Number
Corresponding Author Andrew H Ko, MD, Associate Professor of Medicine, University of California, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1705, San Francisco, CA 94115, United States. andrewko@medicine.ucsf.edu
Key Words Pancreatic cancer; Refractory; Second-line chemotherapy; Gemcitabine
Core Tip No standard of care exists for patients with advanced pancreatic cancer who have progressed on front-line chemotherapy. To date, most available evidence has come from small non-randomized studies, with efficacy results that have been fairly dismal. In this review, we discuss both traditional and novel cytotoxic and targeted therapies that have been evaluated in this refractory setting and how they may (or may not) be applicable to clinical practice; and raise considerations for clinical trial design in the future, particularly in this current era of both expanding chemotherapeutic options and molecular/“precision” medicine.
Publish Date 2014-03-06 14:13
Citation Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236
URL http://www.wjgnet.com/1007-9327/full/v20/i9/2224.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i9.2224
Full Article (PDF) WJG-20-2224.pdf
Full Article (Word) WJG-20-2224.doc
Manuscript File 6398-Review.docx
Answering Reviewers 6398-Answering reviewers.pdf
Copyright License Agreement 6398-Copyright assignment.pdf
Peer-review Report 6398-Peer review(s).pdf
Scientific Editor Work List 6398-Scientific editor work list.doc